WANY
SUPN icon

Wealthspire Advisors (New York)’s Supernus Pharmaceuticals SUPN Stock Holding History

Wealthspire Advisors (New York)’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-44
Closed -$2.1K – 2669
2025
Q3 		$2.1K Buy
+44
New +$1.77K ﹤0.01% 2601

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wealthspire Advisors (New York)'s SUPN Position: Q4 2025 in Review

Wealthspire Advisors (New York) sold out of Supernus Pharmaceuticals (SUPN) in Q4 2025, closing a stake of 44 shares — an estimated $2.1K sold.

Wealthspire Advisors (New York) first reported a position in SUPN in Q3 2025 and held it in 1 quarter. The position peaked at $2.1K in Q3 2025. 333 funds tracked by Wall St. Rank hold SUPN as of Q4 2025.

  • Wealthspire Advisors (New York) reported no remaining Supernus Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Wealthspire Advisors (New York) sold 44 Supernus Pharmaceuticals shares in Q4 2025, an estimated $2.1K.
  • Wealthspire Advisors (New York) first reported a position in Supernus Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Wealthspire Advisors (New York)'s Supernus Pharmaceuticals position peaked at $2.1K in Q3 2025.
  • 333 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2025.

Based on Wealthspire Advisors (New York)'s 13F filing for Q4 2025, filed 13 Feb 2026.